KRAS and colorectal carcinoma: SRC activation has been also implicated in innate or acquired resistance to targeted drugs, such as cetuximab in KRAS mutant CRC [32] or BRAFi in BRAFV600E melanoma patients [33, 34], thus opening new avenues for potential drug manipulation that may eventually expand treatment options and improve the prognosis of these patients.